维多珠单抗治疗克罗恩病继发间质性肾炎及激素安全再挑战:一例病例报告
本文报告一例55岁白人女性因重度克罗恩病接受维多珠单抗输注后发生急性间质性肾炎,排除其他肾病因后使用糖皮质激素治疗,肾功能完全恢复。在缺乏其他治疗选择的情况下,维多珠单抗联合短期激素再挑战耐受良好。文献中单克隆抗体治疗后继发免疫过敏性急性间质性肾炎的病例报告少于10例。
要点
- 维多珠单抗可导致急性间质性肾炎,需警惕输注后肾损伤。
- 糖皮质激素治疗可促进肾功能完全恢复。
- 在无替代方案时,联合激素再挑战维多珠单抗可能耐受良好。
核心结论
- 维多珠单抗治疗克罗恩病可继发急性间质性肾炎,糖皮质激素治疗后可完全恢复,联合激素再挑战耐受良好。
研究设计与样本
- 病例报告:一例55岁白人女性重度克罗恩病患者接受维多珠单抗输注后发生急性间质性肾炎。
主要发现
- 患者接受维多珠单抗输注后发生急性间质性肾炎,排除其他肾病因。
- 使用糖皮质激素后肾功能完全恢复。
- 联合短期激素再挑战维多珠单抗耐受良好。
- 文献中单克隆抗体继发免疫过敏性急性间质性肾炎的病例报告少于10例。
临床怎么用
- 使用维多珠单抗期间应监测肾功能,警惕急性间质性肾炎。
- 发生间质性肾炎时可使用糖皮质激素治疗。
- 在无其他治疗选择时,可考虑联合激素再挑战维多珠单抗。
局限性
- 为单例病例报告,证据级别有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vedolizumab is a gut-selective humanized monoclonal antibody that binds selectively to the α4 β7 integrin and acts as a lymphocyte-homing antagonist. It is indicated in ulcerative colitis and Crohn disease. We report a case of acute interstitial nephritis following vedolizumab infusion in a 55-year-old white woman treated for severe Crohn disease resistant to several therapies. Other kidney disease causes were ruled out. Glucocorticoids were administrated, leading to full renal recovery. In the absence of other therapeutic options, vedolizumab was re-administered along with transient corticosteroids; this treatment was well tolerated. Fewer than 10 cases of immunoallergic acute interstitial nephritis following treatment with monoclonal antibody have previously been reported in the literature. The pathophysiology of delayed-type hypersensitivity secondary to monoclonal antibody therapeutics is discussed in this case report.
引用
- Bailly E, Von Tokarski F, Beau-Salinas F, et al. Interstitial Nephritis Secondary to Vedolizumab Treatment in Crohn Disease and Safe Rechallenge Using Steroids: A Case Report. Am J Kidney Dis. 2017. PMID: 29162338. doi:10.1053/j.ajkd.2017.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。